nandrolone has been researched along with Cancer of Endometrium in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Honda, R; Katabuchi, H; Ohba, T; Saito, F; Suzuki, A; Tashiro, H; Yamaguchi, M | 1 |
Aoki, D; Banno, K; Kisu, I; Kobayashi, Y; Masuda, K; Nomura, H; Susumu, N; Tsuji, K; Ueki, A; Yamagami, W; Yanokura, M | 1 |
Bifulco, G; De Rosa, N; Di Carlo, C; Di Spiezio Sardo, A; Greco, E; Nappi, C; Spinelli, M; Tommaselli, GA | 1 |
Arterburn, JB; Dai, D; Hathaway, HJ; Nayak, TK; Norenberg, JP; Prossnitz, ER; Ramesh, C; Sklar, LA | 1 |
Botella, J; Delansorne, R; Duc, I; Duranti, E; Paris, J; Viader, V | 1 |
Aoki, D; Katsuki, Y; Nozawa, S; Shibutani, Y | 1 |
Skouby, SO | 1 |
2 review(s) available for nandrolone and Cancer of Endometrium
Article | Year |
---|---|
Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
Topics: Animals; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Nandrolone; Progestins | 2012 |
The rationale for a wider range of progestogens.
Topics: Androstenes; Biological Availability; Breast Neoplasms; Cardiovascular Diseases; Contraindications; Endometrial Neoplasms; Estranes; Estrogen Replacement Therapy; Female; Gonanes; Humans; Nandrolone; Osteoporosis, Postmenopausal; Pregnanes; Primary Prevention; Progestins; Treatment Outcome | 2000 |
5 other study(ies) available for nandrolone and Cancer of Endometrium
Article | Year |
---|---|
Development of a mouse model for testing therapeutic agents: the anticancer effect of dienogest on endometrial neoplasms.
Topics: Animals; Antineoplastic Agents, Hormonal; Disease Models, Animal; Endometrial Neoplasms; Female; Medroxyprogesterone Acetate; Mice; Nandrolone; Progestins; Treatment Outcome | 2016 |
The use of an oral contraceptive containing estradiol valerate and dienogest before office operative hysteroscopy: a feasibility study.
Topics: Adult; Case-Control Studies; Contraceptives, Oral, Combined; Drug Combinations; Endometrial Neoplasms; Endometrium; Estradiol; Feasibility Studies; Female; Hospitals, University; Humans; Hysteroscopy; Nandrolone; Operative Time; Outpatient Clinics, Hospital; Pain, Postoperative; Pilot Projects; Polyps; Preoperative Care; Prospective Studies; Sterilization, Tubal; Uterus | 2012 |
Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Dihydrotestosterone; Drug Delivery Systems; Drug Evaluation, Preclinical; Endometrial Neoplasms; Female; Humans; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Nandrolone; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Estrogen; Tissue Distribution | 2008 |
Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells.
Topics: Adenocarcinoma; Alkaline Phosphatase; Aminoglutethimide; Aromatase Inhibitors; Binding, Competitive; Cytosol; Endometrial Neoplasms; Endometrium; Enzyme Induction; Enzyme Inhibitors; Estradiol Congeners; Estrogens; Ethinyl Estradiol; Female; Humans; Nandrolone; Norpregnanes; Norprogesterones; Pregnanes; Progesterone; Progestins; Receptors, Estrogen; Tamoxifen; Testosterone; Tumor Cells, Cultured | 1995 |
Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Hormone Antagonists; Humans; Mice; Mice, SCID; Nandrolone; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 1997 |